Paxlovid Tied to Benefits in High-Risk Patients With COVID :

The use of nirmatrelvir–ritonavir (Paxlovid) is associated with a lower risk for death or hospitalization in extremely vulnerable patients with COVID-19. Low-risk patients do not appear to benefit.

Related Keywords

United Kingdom , Canada , Vancouver , British Columbia , Ohio , United States , British , Colinr Dormuth , , University Of British Columbia , British Columbia Ministry Of Health , Medscape Coronavirus Resource Center , Coronavirus Resource , Medscape Medical , High Risk Patients , Cleveland Clinic , British Columbia Ministry , Published October , Covid 19 Treatment , Coronavirus , 019 Novel Coronavirus , 019 Ncov , Uhan Coronavirus , Uman Coronavirus Hku1 , Uman Coronavirus Oc43 , Cov Oc43 , Uman Coronavirus 229e , Cov 229e , Inpatient Care , Immunocompromise , Immunocompromised , Clinical Research , Clinical Trials , Linical Studies , Hospitals , Immunizations , Vaccination , Covid 19 Omicron Variant , Ovid 19 Omicronb 1 529 Variant , Ovid 19b 1 5 ,